Literature DB >> 23857974

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.

Liliana Devizzi, Anna Guidetti, Ettore Seregni, Roberto Passera, Marco Maccauro, Michele Magni, Adele Testi, Massimo Di Nicola, Corrado Tarella, Paola Matteucci, Simonetta Viviani, Marco Ruella, Carmelo Carlo-Stella, Carlo Chiesa, Maria Cristina Cox, Emilio Bombardieri, Alessandro M Gianni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23857974      PMCID： PMC3732314          DOI： 10.1200/JCO.2013.50.2922

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

Authors:  Avichai Shimoni; S Tzila Zwas; Yakov Oksman; Izhar Hardan; Noga Shem-Tov; Ronit Yerushalmi; Abraham Avigdor; Isaac Ben-Bassat; Arnon Nagler
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.

Authors:  Ravi Bhatia; Khristine Van Heijzen; Ann Palmer; Asako Komiya; Marilyn L Slovak; Karen L Chang; Henry Fung; Amrita Krishnan; Arturo Molina; Auayporn Nademanee; Margaret O'Donnell; Leslie Popplewell; Roberto Rodriguez; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

4.  Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Authors:  Thomas E Witzig; Christine A White; Leo I Gordon; Gregory A Wiseman; Christos Emmanouilides; James L Murray; John Lister; Pratik S Multani
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Authors:  Avichai Shimoni; Irit Avivi; Jacob M Rowe; Moshe Yeshurun; Itai Levi; Reuven Or; Paulina Patachenko; Abraham Avigdor; Tzila Zwas; Arnon Nagler
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

Review 6.  Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.

Authors:  James O Armitage; Paul P Carbone; Joseph M Connors; Alexandra Levine; John M Bennett; Stewart Kroll
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

7.  Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

Authors:  Leo I Gordon; Thomas Witzig; Arturo Molina; Myron Czuczman; Christos Emmanouilides; Robin Joyce; Katie Vo; Charles Theuer; Brad Pohlman; Nancy Bartlett; Greg Wiseman; Mohamed Darif; Christine White
Journal:  Clin Lymphoma       Date:  2004-09

8.  Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

Authors:  Russell Schilder; Arturo Molina; Nancy Bartlett; Thomas Witzig; Leo Gordon; James Murray; Stewart Spies; Hua Wang; Gregory Wiseman; Christine White
Journal:  Cancer Biother Radiopharm       Date:  2004-08       Impact factor: 3.099

9.  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

Authors:  Leo I Gordon; Arturo Molina; Thomas Witzig; Christos Emmanouilides; Andrew Raubtischek; Mohamed Darif; Russell J Schilder; Greg Wiseman; Christine A White
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

10.  Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.

Authors:  Christos Emmanouilides; Thomas E Witzig; Gregory A Wiseman; Leo I Gordon; Hua Wang; Russell Schilder; M Wayne Saville; Ian Flinn; Arturo Molina
Journal:  Cancer Biother Radiopharm       Date:  2007-10       Impact factor: 3.099
View more
  2 in total

Review 1.  The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era.

Authors:  Francesco Maura; Lucia Farina; Paolo Corradini
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

2.  Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.

Authors:  Victor A Chow; Ryan D Cassaday; Theodore A Gooley; Stephen D Smith; Brenda M Sandmaier; Damian J Green; Johnnie J Orozco; Sherilyn A Tuazon; Manuela Matesan; Darrell R Fisher; David G Maloney; Oliver W Press; Ajay K Gopal
Journal:  Blood Adv       Date:  2022-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.